Axsome's depression drug, Auvelity, is driving the top line while Sunosi diversifies its business. The recent FDA nod for Symbravo also bodes well.

Arizona State Retirement System lifted its holdings in Axsome Therapeutics, Inc. (NASDAQ:AXSM – Free Report) by 1.8% in the ...

Like most other drugs, Auvelity can cause side effects. Hair loss was not reported in the drug’s studies, but it has been reported since the drug was made available on the market. Auvelity can ...

Based on the FDA's feedback, Axsome plans to submit a supplemental NDA for AXS-05 in Alzheimer's disease agitation in third-quarter 2025.

AXS-05 is already approved for treating adults with major depressive disorder (MDD) and is being marketed under the brand name Auvelity. Auvelity is the biggest product in Axsome’s portfolio.

Axsome's flagship product, AUVELITY (AXS-05), has been approved for the treatment of major depressive disorder (MDD) and is showing strong commercial performance. The company is now exploring the ...

Total net product revenue reached $386 million for 2024, with CEO Tabuteau stating, "Based on the recent performance, Auvelity is on track to reach blockbuster potential." Symbravo received FDA ...

It has two commercial products, Auvelity and Sunosi, and several products in development, including AXS-05 and AXS-07. On March 6, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on the ...

Baird raised the firm’s price target on Axsome Therapeutics (AXSM) to $160 from $132 and keeps an Outperform rating on the shares. The firm ...